GRCL
Income statement / Annual
Last year (2022), Gracell Biotechnologies Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2022, Gracell Biotechnologies Inc.'s net income was -$607.51 M.
See Gracell Biotechnologies Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$366,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$366,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
1
|
0
|
0
|
0
|
| Research and Development Expenses |
$485.39 M
|
$326.90 M
|
$168.83 M
|
$119.22 M
|
$52.24 M
|
| General & Administrative Expenses |
$139.27 M
|
$137.04 M
|
$45.57 M
|
$27.36 M
|
$10.26 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$139.27 M
|
$137.04 M
|
$45.57 M
|
$27.36 M
|
$10.26 M
|
| Other Expenses |
$8.16 M
|
$9.06 M
|
$4.70 M
|
$1.43 M
|
$276,000.00
|
| Operating Expenses |
$624.66 M
|
$463.94 M
|
$214.40 M
|
$146.58 M
|
$62.50 M
|
| Cost And Expenses |
$624.66 M
|
$463.94 M
|
$214.40 M
|
$146.58 M
|
$62.50 M
|
| Interest Income |
$23.92 M
|
$9.12 M
|
$2.87 M
|
$3.93 M
|
$1.44 M
|
| Interest Expense |
$6.74 M
|
$5.06 M
|
$2.16 M
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$32.08 M
|
$78.45 M
|
$7.57 M
|
$2.57 M
|
$2.99 M
|
| EBITDA |
-$592.58 M |
-$385.13 M |
-$206.83 M |
-$144.01 M |
-$57.80 M |
| EBITDA Ratio |
0
|
-1052.26
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
-1266.59
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$17.17 M
|
$11.82 M
|
$2.50 M
|
$7.92 M
|
$1.71 M
|
| Income Before Tax |
-$607.49 M
|
-$451.75 M
|
-$211.90 M
|
-$138.66 M
|
-$60.79 M
|
| Income Before Tax Ratio |
0
|
-1234.3
|
0
|
0
|
0
|
| Income Tax Expense |
$22,000.00
|
$14.13 M
|
-$14.74 M
|
-$6.49 M
|
$1.71 M
|
| Net Income |
-$607.51 M
|
-$465.88 M
|
-$197.16 M
|
-$132.18 M
|
-$60.79 M
|
| Net Income Ratio |
0
|
-1272.9
|
0
|
0
|
0
|
| EPS |
-5.65 |
-7.08 |
-3.01 |
-6.67 |
-3.07 |
| EPS Diluted |
-5.65 |
-7.08 |
-3.01 |
-6.67 |
-3.07 |
| Weighted Average Shares Out |
$107.49 M
|
$65.77 M
|
$65.56 M
|
$19.81 M
|
$19.81 M
|
| Weighted Average Shares Out Diluted |
$107.49 M
|
$65.77 M
|
$65.56 M
|
$19.81 M
|
$19.81 M
|
| Link |
|
|
|
|
|
